FDA Grants Fast Track Designation to Daretabart for High-Risk Neuroblastoma Treatment
Key Insights
The FDA has granted Fast Track Designation to daretabart (search) (hu1418K322A), a novel anti-GD2 (search) monoclonal antibody for treating high-risk neuroblastoma, recognizing significant unmet medical need in this rare pediatric cancer.
FDA clearance of the IND application enables initiation of the SHINE Phase II/III clinical trial in relapsed and refractory high-risk neuroblastoma patients in the United States.
Previous Phase II data demonstrated encouraging results with daretabart (search) showing a three-year overall survival rate of 86.0% and event-free survival rate of 73.7% when integrated into frontline therapy.
The US Food and Drug Administration has granted Fast Track Designation to daretabart (search) (hu1418K322A), a novel anti-GD2 (search) monoclonal antibody developed by Renaissance Pharma Limited (search) for treating high-risk neuroblastoma, a rare and aggressive pediatric cancer. The designation recognizes the significant unmet medical need in this patient population and provides access to accelerated and rolling review processes.
Concurrent with the Fast Track Designation, the FDA cleared Renaissance Pharma's investigational new drug (IND) application, enabling the initiation of the SHINE Phase II/III clinical trial in the United States for patients with relapsed or refractory high-risk neuroblastoma. The company has also successfully manufactured the first commercial-scale Good Manufacturing Practice (GMP) batch of daretabart (search) for use in the upcoming trial.
Targeting GD2 Antigen with Novel Modifications
Daretabart (search) is being developed under an exclusive license agreement with St. Jude Children's Research Hospital, a global leader in pediatric cancer research and treatment. The antibody targets GD2 (search), a cell surface antigen highly expressed on neuroblastoma cells. By binding to GD2, daretabart is designed to enhance immune-mediated tumor cell killing while incorporating novel structural modifications intended to improve the tolerability profile.
Strong Phase II Efficacy Data
The clinical development program builds on encouraging Phase II data from a study (NCT01857934) that evaluated daretabart (search) as part of first-line therapy and in the post-consolidation setting for patients with high-risk neuroblastoma. The open-label, single-arm trial enrolled children younger than 19 years with newly diagnosed high-risk neuroblastoma.
Results published in the Journal of Clinical Oncology in December 2021 demonstrated that integration of daretabart (search) into induction chemotherapy significantly improved long-term outcomes. The study showed a three-year event-free survival rate of 73.7% (95% CI, 60.0%-83.4%) and an overall survival rate of 86.0% (95% CI, 73.8%-92.8%). Partial responses or better after the first two chemoimmunotherapy cycles were observed in 66.7% of patients (95% CI, 55.0%-78.3%).
The treatment regimen included four daily doses of 40 mg/m² of daretabart (search) administered over four hours on days 2 to 5, given concurrently with each cycle of induction chemotherapy. The regimen was well tolerated with continuous infusion narcotics.
Addressing Critical Unmet Need
Neuroblastoma represents 7-10% of all childhood cancers and is the most common extracranial cancer in children, as well as the most common cancer in children under one year of age. Each year, more than 1,500 people are diagnosed in Europe and 800 in the United States. Approximately half of all neuroblastoma patients have high-risk disease, which carries an overall five-year survival rate of approximately 50%.
Current standard of care is intensive and multimodal, including chemotherapy, surgery, radiotherapy, stem cell transplantation, and anti-GD2 (search) monoclonal antibody treatment. Despite these interventions, a significant unmet medical need remains for more effective and better-tolerated treatments.
Commercial Manufacturing Milestone
The successful manufacture of the first commercial-scale GMP batch represents a key operational milestone and underscores Renaissance Pharma's commitment to ensuring reliable, high-quality supply as the program advances. This achievement supports ongoing clinical development and represents an important step toward future commercial readiness.
"Daretabart (search) has the potential to make a real difference for children with high-risk neuroblastoma, a disease where outcomes remain deeply inadequate despite intensive treatment," said Simon Ball, Interim CEO of Essential Pharma (search) and Director of Renaissance Pharma Limited (search). "FDA Fast Track Designation is an important external validation of that potential, and together with IND clearance and our ability to manufacture at commercial scale, reflects the strength and maturity of this programme."
The upcoming SHINE Phase II/III study will specifically evaluate the efficacy and safety of daretabart (search) in pediatric patients with relapsed or refractory high-risk neuroblastoma, building on the promising results observed in the frontline setting.